Roche has extended its tender offer period relating to its pending $4.3-billion acquisition of Spark Therapeutics, a Philadelphia-based gene-therapy company, from September 3, 2019 to October 1, 2019. Roche had previously extended the offer period from July 31 to September 3.

Roche says the offer was extended to provide additional time for the US Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) to complete their previously disclosed reviews of Roche’s pending acquisition of Spark. Roche says the parties remain committed to the transaction and are working with the FTC and CMA.

The tender offer to purchase shares of Spark Therapeutics is for $114.50 per share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the original offer from March 7, 2019. Roche says all terms and conditions of the offer shall remain unchanged during the extended period. Roche had announced its acquisition of Spark Therapeutics in February 2019.

Source: Roche